Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07810933) titled 'A Phase 1/2 Study of SY-12321 in Patients With ALK-positive Advanced Malignancies' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shouyao Holdings (Beijing) Co. LTD
Condition:
ALK Positive Advanced Malignancies
Intervention:
Drug: SY-12321
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 12, 2026
Target Sample Size: 330
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07810933
Disclaim...